Walvax Biotechnology Co., Ltd

Founded in 2001, Walvax Biotechnology Co., Ltd. (Walvax) is a leading vaccine producer, engaged in research and development, manufacturing and distribution of safe and efficacious quality vaccines.Headquartered in China’s southwestern city Kunming, Yunnan Province, Walvax went public via IPO in 2010 (300142.SZ) and started business expansion from traditional vaccines to innovative vaccines.With the vision of dedicating to be the pride domestically and the pioneer globally in the vaccine industry, Walvax produces efficacious, quality, innovative and affordable products to protect people from the world’s deadliest diseases, for the purpose of helping everyone live a healthy life.

Walvax has established advanced platforms for the research and development of polysaccharide and conjugate vaccines, recombinant protein and VLP vaccines, and mRNA vaccines. Meanwhile, Walvax has successfully developed 9 licensed vaccines (13 presentations), including SARS-CoV-2 mRNA Vaccine, 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13), Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (HPV2), 23-valent pneumococcal polysaccharide (PPSV23), Group ACYW135 meningococcal polysaccharide vaccine(MPV ACYW135), Group A and C meningococcal polysaccharide vaccine (MPV AC), Group A and group C meningococcal conjugate vaccine (MCV AC), Haemophilus influenza type b conjugate vaccine (Hib), and Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine (DTaP).

Walvax’s products has been distributed to 31 provinces, more than 220 cities and more than 2,400 counties in China. Beyond China, Walvax has worked closely with business partners to reach overseas markets, and has been exporting vaccines to 18 countries, including Indonesia, the United States, Morocco, Uzbekistan, Egypt, the Philippines, Bangladesh, Guinea, Nigeria, Senegal, Mauritius, Niger, India, Kyrgyzstan, etc.

In the global collaboration area, Walvax and its subsidiaries have been partnering with academic institutions, industry peers and international organizations. Hitherto, Walvax has received three grants worth US$ 8.5 million in total from the Bill & Melinda Gates Foundation to support WHO prequalification for the HPV2 and HPV9 in order to prepare for UNICEF procurement for Gavi countries, and to expedite pre-clinical research of Recombinant Subunit SARS-CoV-2 Vaccine as well. Walvax has also partnered with CEPI and expanded collaboration to develop COVID-19 multi-variant vaccine. In addition, HPV2 and MPV ACYW135 are under WHO-PQ assessment, while PCV13 is undergoing WHO-PQ preparations.

Contact us at: globalmarketing@walvax.com and bd@walvax.com for collaboration discussion.